C
COGNITION THERAPEUTICS INC
NASDAQ: CGTX (Cognition Therapeutics, Inc.)
Last update: 15 minutes ago1.66
-0.03 (-1.78%)
| Previous Close | 1.69 |
| Open | 1.68 |
| Volume | 1,386,166 |
| Avg. Volume (3M) | 5,475,454 |
| Market Cap | 146,451,632 |
| Price / Book | 17.95 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.730 |
| Total Debt/Equity (MRQ) | 5.18% |
| Current Ratio (MRQ) | 2.09 |
| Operating Cash Flow (TTM) | -31.11 M |
| Levered Free Cash Flow (TTM) | -31.63 M |
| Return on Assets (TTM) | -107.53% |
| Return on Equity (TTM) | -161.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Cognition Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.81% |
| % Held by Institutions | 18.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bios Capital Management, Lp | 30 Jun 2025 | 6,000,000 |
| Davenport & Co Llc | 30 Sep 2025 | 2,689,336 |
| Acadian Asset Management Llc | 30 Jun 2025 | 701,940 |
| Chescapmanager Llc | 30 Jun 2025 | 503,259 |
| Voss Capital, Lp | 30 Jun 2025 | 450,000 |
| Cm Management, Llc | 30 Jun 2025 | 250,000 |
| Kestra Advisory Services, Llc | 30 Jun 2025 | 155,934 |
| Sigma Planning Corp | 30 Jun 2025 | 147,990 |
| Two Sigma Investments, Lp | 30 Jun 2025 | 95,199 |
| Mcadam, Llc | 30 Sep 2025 | 72,075 |
| 52 Weeks Range | ||
| Median | 4.00 (140.96%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 08 Aug 2025 | 4.00 (140.96%) | Buy | 0.755 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |